达雷妥尤单抗治疗肺癌合并持续性血小板减少的难治性 IgD 多发性骨髓瘤：病例报告
Daratumumab for Refractory IgD Multiple Myeloma with Lung Cancer and Persistent Thrombocytopenia: a Case Report.
出版信息
Clin Lab. 2021 Nov 1;67(11). doi: 10.7754/Clin.Lab.2021.210405.
BACKGROUND
Immunoglobulin D multiple myeloma (IgD-MM) is a rare but aggressive disease. The safety and effectiveness of anti-CD38 monoclonal antibody (daratumumab) have not been known in either IgD-MM or MM complicated with secondary neoplasm.
METHODS
A fragile IgD-MM patient had an aggressively relapsed disease concurrent with lung cancer and severe thrombocytopenia, which led to a dilemma for management. After a failure of ixazomib-based chemotherapy, a salvage therapy with daratumumab unexpectedly induced complete remission and platelet recovery, and the patient successfully proceeded to lung cancer surgery.
CONCLUSIONS
Our case indicates daratumumab is both safe and effective for refractory IgD-MM with severe complications.
背景
免疫球蛋白 D 多发性骨髓瘤（IgD-MM）是一种罕见但侵袭性很强的疾病。抗 CD38 单克隆抗体（达雷妥尤单抗）在 IgD-MM 或伴有继发肿瘤的 MM 中的安全性和有效性尚不清楚。
方法
一位脆弱的 IgD-MM 患者患有肺癌和严重血小板减少症的侵袭性复发疾病，这导致了管理上的困境。在基于伊沙佐米的化疗失败后，达雷妥尤单抗的挽救性治疗意外地诱导了完全缓解和血小板恢复，患者成功地进行了肺癌手术。
结论
我们的病例表明，达雷妥尤单抗对于伴有严重并发症的难治性 IgD-MM 既安全又有效。
Zotero 插件